Serbia - Press Releases

CHANDLER, Ariz., Feb. 12, 2025 /PRNewswire/ --Embark Behavioral Health, a leader in youth and young adult mental health care, is reaffirming its commitment to creating joy and healing generations. Under the leadership of Scott Filion, CEO, and Dr. Sharnell Myles, Psy.D., Chief Clinical Officer, the company is fortifying its mission through a revitalized clinical leadership team and expanding their current services to offer integrated mental health.

OMAHA, Neb., Feb. 12, 2025 /PRNewswire/ -- IHS, LLC., a leading business acquisitions and management firm, along with its physician partners, proudly announces the successful acquisition of BC Healthcare, a distinguished specialty medical practice recognized for its advanced healthcare services. This strategic acquisition marks a significant milestone in IHS, LLC.'s commitment to expanding high-quality, patient-centered care and elevating healthcare standards in Omaha, Nebraska, and beyond.

PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ --Palindrome Technologies has been recognized as an official testing facility for the IEEE Medical Device Cybersecurity Certification Program, positioning the company at the forefront of medical device security. This certification program, launched in 2023 by the IEEE 2621 Conformity Assessment Committee (CAC), offers a comprehensive evaluation process tailored specifically for medical devices in an increasingly connected healthcare landscape.

HONG KONG, Feb. 12, 2025 /PRNewswire/ --Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bispecific antibody, cadonilimab. This study is evaluating the efficacy of cadonilimab compared to sugemalimab (PD-L1) as a consolidation therapy for patients with locally advanced, non-resectable, non-small cell lung cancer (NSCLC) who have not experienced disease progression following concurrent or sequential chemoradiotherapy.

NEW YORK, LONDON, MNCHEN und NEU-DELHI, 13. Februar 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG), gibt die Ernennung von Dr. Massimo Cristofanilli, MD, zum strategischen Berater bekannt. DCG ist ein weltweit fhrendes Unternehmen im Bereich der nicht-invasiven Krebsdiagnostik. Mit diesem Schritt unterstreicht DCG sein Engagement fr die Weiterentwicklung der Krebsfrherkennung und Przisionsmedizin.

CHENGDU, China, Feb. 12, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025,Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd "Kelun-Biotech" will present efficacy and safety results from the Phase 1/2 KL264-01/MK-2870-001 study (NCT04152499) of its anti-TROP2ADC sacituzumab tirumotecan (sac-TMT, formerly SKB-264/MK-2870) as monotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (UC) who progressed on or after prior anti-cancer therapies. These findings will be presented in a poster session on February 14, 2025, local time (Abstract #796).

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

TOKYO, Feb. 13, 2025 /PRNewswire/ --Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been dosed atKeio University Hospital. RV-001 utilizes adeno-associated virus (AAV) vectors to deliver a unique functional gene encoding "Chimeric Rhodopsin", a light-driven G-protein activation mechanism to re-establish light activation in retinal interneurons. The goal is to expand light sensitivity to retinal interneurons via an intravitreal injection of RV-001. This milestone marks the initiation of the world's first clinical trial of optogenetic gene therapy, which leverages a proprietary "Chimeric Rhodopsin" for patients with retinitis pigmentosa (RP). "Over 2 million people worldwide suffer photoreceptor loss in retinitis pigmentosa, resulting in severe vision loss and eventual blindness" said, CEO and Ophthalmologist Yusaku Katada, MD, PhD. "Our "chimeric rhodopsin" approach has broad potential to alter light sensitivity across multiple subtypes of RP patients.[1] We are continuing to advance the Phase I/II trial to assess safety, light-activation and light-sensitivity in these patients, post-administration of our lead gene therapy product RV-001."

VADUZ, Liechtenstein, Feb. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding.

SHANGHAI and HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that XPOVIO (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least two prior therapies, has been approved for reimbursement in Taiwan. Starting from March 1, 2025, XPOVIO will be officially included in the NHI drug reimbursement scheme.

HUNTINGTON BEACH, Calif., Feb. 12, 2025 /PRNewswire/ -- Karman Holdings Inc. ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile and defense, and space programs, today announced the pricing of its initial public offering of 23,000,000 shares of its common stock at a public offering price of $22.00 per share (the "Common Stock"). The offering consists of 8,421,053 shares of Common Stock offered by Karman and 14,578,947 shares of Common Stock to be sold by certain of Karman's existing stockholders (the "Selling Stockholders"). Karman will not receive any proceeds from the sale of Common Stock by the Selling Stockholders. The shares of Karman's Common Stock are expected to begin tradingontheNewYorkStock Exchangeunderthetickersymbol "KRMN"onFebruary 13, 2025, and the offering is expected to close on February 14, 2025, subject to customary closing conditions.

The accomplished global business executive will oversee the firm's strategic growth initiatives for the Asia-Pacific region.

Kojamo plc Stock Exchange Release, 13 February 2025 at 8:30 a.m. EET

Le projet ASK de l'ESA exploite l'IA pour optimiser la performance et le partage des connaissances au sein d'une grande organisation intergouvernementale.

ASK ESA project uses AI to increase efficiency and share knowledge across major intergovernmental organization

Kojamo plc Stock Exchange Release 13 February 2025 at 9.00 a.m. EET

CALIFORNIA CITY, Calif., Feb. 13, 2025 /PRNewswire/ -- Hyundai America Technical Center, Inc. (HATCI) held a celebration event earlier this week in honor of 20 successful years of quality and performance testing at its California Proving Ground (CPG) in California City, Calif. The $80 million facility, which opened in 2005, has seen more than 5,000 Hyundai Motor, Kia, and Genesis vehicles undergo rigorous testing on a variety of roads and in extreme conditions to ensure their quality, durability, reliability, and safety.

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- Hanon Systems (KS:018880), a leading global automotive thermal management supplier, has been included in the S&P Global Sustainability Yearbook for the second consecutive year.

Customers can earn points on every cruise and redeem for exclusive rewards

GUANGZHOU, China, Feb. 13, 2025 /PRNewswire/ -- As China's No.1 platform for international trade, the 137th Canton Fair has successfully hosted a Southeast Asiaroadshow with trade promotion events in Vietnam, Laos and Cambodia in January.

TORONTO, Feb. 13, 2025 /PRNewswire/ - Indeed Labs, the award-winning Canadian skincare brand renowned for making science-backed beauty accessible, introduces an exciting new lineup of products designed to meet the needs of a new generation. Featuring a two-in-one cleanser, a milky toner, a brightening serum, and breakthrough microdarts, these products prioritize simplicity, effectiveness, and skin health for all ages, with a special focus on Generation Alpha and Gen Z.

LUXEMBOURG, 13 ubat 2025 /PRNewswire/ -- Ferrero Grubu, holding irketi Ferrero International S.A. araclyla, 31 Austos 2024'te sona eren 2023/24 mali ylna ilikin konsolide finansal sonularn aklad. Grup, bir nceki yla gre yzde 8,9 orannda artla, yl 18,4 milyar avroluk konsolide ciroyla tamamlad. Byme trendi, Ferrero Grubu Ynetim Kurulu Bakan Giovanni Ferrero'nun liderliinde ve Ferrero Grubu CEO'su Lapo Civiletti'nin yrtt stratejiyle gerekleti.

LUXEMBOURG, Feb. 13, 2025 /PRNewswire/ -- The Ferrero Group, through its holding company Ferrero International S.A., approved the Consolidated Financial Statements for the 2023/2024 financial year, which ended on August 31, 2024[1]. The Group closed the financial year with a consolidated turnover of EUR18.4 billion, an increase of 8.9% compared to the previous year, thus continuing the growth strategy driven by Executive Chairman Giovanni Ferrero and executed by Chief Executive Officer Lapo Civiletti.

LUXEMBOURG, Feb. 13, 2025 /PRNewswire/ -- The Ferrero Group, through its holding company Ferrero International S.A., approved the Consolidated Financial Statements for the 2023/2024 financial year, which ended on August 31, 2024[1]. The Group closed the financial year with a consolidated turnover of EUR18.4 billion, an increase of 8.9% compared to the previous year, thus continuing the growth strategy driven by Executive Chairman Giovanni Ferrero and executed by Chief Executive Officer Lapo Civiletti.

TORONTO, Feb. 12, 2025 /PRNewswire/ --Waste Connections, Inc. (TSX/NYSE: WCN) ("Waste Connections" or the "Company") today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.315 U.S. per common share of the Company. The regular quarterly cash dividend will be paid on March 13, 2025 to shareholders of record at the close of business on February 27, 2025. The Board intends to review the quarterly dividend each October, with a long-term objective of increasing the amount of the dividend.